ライフサイエンスコーパス: alcoholic fatty liver

1 tissue (WAT)-liver axis in a mouse model of alcoholic fatty liver.

2 een adipose fat loss and hepatic fat gain in alcoholic fatty liver.

3 the plasma leptin concentration and reversed alcoholic fatty liver.

4 to diseases like obesity, diabetes, and non-alcoholic fatty liver.

5 be a cryptic co-factor in some cases of non-alcoholic fatty liver.

6 n, fatty acid metabolism, and development of alcoholic fatty liver.

7 ethanol may contribute to the development of alcoholic fatty liver.

8 mediated fatty acid uptake may contribute to alcoholic fatty liver.

9 as significantly higher in patients with non-alcoholic fatty liver.

10 rity of liver steatosis in subjects with non-alcoholic fatty liver.

11 ers of oxidative stress in subjects with non-alcoholic fatty liver.

12 e in alcoholic liver disease, which includes alcoholic fatty liver, alcoholic hepatitis, and alcoholi

13 PGF2alpha were independent predictors of non-alcoholic fatty liver and a strong association of urinar

14 xidative stress markers in patients with non-alcoholic fatty liver and no study has been performed wi

15 ct of ethanol may promote the development of alcoholic fatty liver and other hepatic consequences of

16 isease, type 2 diabetes, atherosclerosis,non-alcoholic fatty liver, and cancer.

17 E-selectin was highly up-regulated in human alcoholic fatty livers, but not in alcoholic cirrhosis.

18 In animal models for alcoholic fatty liver disease (AFLD), decontaminating th

19 Alcoholic fatty liver disease (ALD) and nonalcoholic fat

20 Participants with non-alcoholic fatty liver disease (defined as (1)H magnetic

21 s and in a human cohort of subjects with non-alcoholic fatty liver disease (N = 146).

22 Non-alcoholic and alcoholic fatty liver disease (NAFLD and AFLD, respectiv

23 models (n = 3-5) and in human samples of non-alcoholic fatty liver disease (NAFLD) (n = 72-135).

24 Non-alcoholic fatty liver disease (NAFLD) affects a large pr

25 Non-alcoholic fatty liver disease (NAFLD) and cardiovascular

26 gut microbiota in choline deficiency in non-alcoholic fatty liver disease (NAFLD) and insulin resist

27 Non-alcoholic fatty liver disease (NAFLD) and its more sever

28 milar to those observed in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic

29 ne fetuin-A may impair renal function in non alcoholic fatty liver disease (NAFLD) by altering inflam

30 erum XPO4 pattern in a broad spectrum of non-alcoholic fatty liver disease (NAFLD) cases.

31 Non-alcoholic fatty liver disease (NAFLD) characterizes and

32 and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon emerge

33 The approach was developed on a non-alcoholic fatty liver disease (NAFLD) data set.

34 non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from routi

35 Non-alcoholic fatty liver disease (NAFLD) has been recently

36 iver function in bariatric patients with non-alcoholic fatty liver disease (NAFLD) in a randomized cl

37 ent studies have raised the concept that non-alcoholic fatty liver disease (NAFLD) in adults is disti

38 Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T

39 The incidence of non-alcoholic fatty liver disease (NAFLD) increases with age

40 Non-alcoholic fatty liver disease (NAFLD) is a common metabo

41 Non-alcoholic fatty liver disease (NAFLD) is a major risk fa

42 Non-alcoholic fatty liver disease (NAFLD) is an increasingly

43 Non-alcoholic fatty liver disease (NAFLD) is becoming the le

44 Non-alcoholic fatty liver disease (NAFLD) is defined as a sp

45 he gut microbiome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is emerging.

46 Non-alcoholic fatty liver disease (NAFLD) is one of the most

47 Non-alcoholic fatty liver disease (NAFLD) is one of the most

48 Non-alcoholic fatty liver disease (NAFLD) is one of the most

49 The prevailing theory in non-alcoholic fatty liver disease (NAFLD) is the "two-hit" h

50 Non-alcoholic fatty liver disease (NAFLD) is the hepatic man

51 Non-alcoholic fatty liver disease (NAFLD) is the most common

52 Non-alcoholic fatty liver disease (NAFLD) is the most common

53 ted genes in the gastric tissue of obese non-alcoholic fatty liver disease (NAFLD) patients.

54 Non-alcoholic fatty liver disease (NAFLD) represents a spect

55 The process initiates with non-alcoholic fatty liver disease (NAFLD) that progresses to

56 Increasing evidence connects non-alcoholic fatty liver disease (NAFLD) to CKD.

57 FXR and CAR in disease progression from non-alcoholic fatty liver disease (NAFLD) to HCC.

58 There is no licensed treatment for non-alcoholic fatty liver disease (NAFLD), a condition that

59 6), overweight children with and without non-alcoholic fatty liver disease (NAFLD), and children with

60 ly affected by the metabolic syndrome as non-alcoholic fatty liver disease (NAFLD), but may contribut

61 ome (PCOS) is frequently associated with non-alcoholic fatty liver disease (NAFLD), but the mechanism

62 tophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), however the mecha

63 In non-alcoholic fatty liver disease (NAFLD), lipid build-up an

64 od spot testing-is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD), non-alcoholic ste

65 h chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs1297

66 ng recessive male-specific lethality and non-alcoholic fatty liver disease (NAFLD), which coincides w

67 Non-alcoholic fatty liver disease (NAFLD), which includes st

68 ic control in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD).

69 creased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

70 ein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD).

71 isms differ in drug induced (DIS) and/or non-alcoholic fatty liver disease (NAFLD).

72 creased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

73 as a potential plasma marker to diagnose non-alcoholic fatty liver disease (NAFLD).

74 BR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD).

75 icacy of sevelamer in treating mice with non-alcoholic fatty liver disease (NAFLD).

76 Visceral obesity is often accompanied by non-alcoholic fatty liver disease (NAFLD).

77 eatosis both in an inbred mouse model of non-alcoholic fatty liver disease (SJL/J) and in a humanized

78 liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at least

79 t), as well as elevated inflammation and non-alcoholic fatty liver disease activity scores, and hepat

80 both the metabolic syndrome accompanying non-alcoholic fatty liver disease and cellular apoptosis, we

81 Increases in non-alcoholic fatty liver disease and drug-induced hepatotox

82 Non-alcoholic fatty liver disease and early fibrosis were in

83 Non-alcoholic fatty liver disease and its downstream sequela

84 a substantial overlap with biomarkers of non-alcoholic fatty liver disease and its progression to ste

85 Low aerobic capacity increases risk for non-alcoholic fatty liver disease and liver-related disease

86 ma lipoprotein metabolism, alcoholic and non-alcoholic fatty liver disease and myocardial infarction

87 o be of relevance for the development of non-alcoholic fatty liver disease and obesity.

88 r treating inflammatory diseases such as non-alcoholic fatty liver disease and type 2 diabetes.

89 to various metabolic diseases, including non-alcoholic fatty liver disease and type 2 diabetes.

90 could alleviate the related epidemics of non-alcoholic fatty liver disease and type 2 diabetes.

91 Ninety four eligible patients who have non-alcoholic fatty liver disease and who are insulin resist

92 lications such as insulin resistance and non-alcoholic fatty liver disease are reaching epidemic prop

93 UT2 may contribute to the development of non-alcoholic fatty liver disease by facilitating the uptake

94 5 in vivo prior to or after establishing non-alcoholic fatty liver disease in mice.

95 y, and prevents metabolic stress-induced non-alcoholic fatty liver disease in mice.

96 fat accumulation and provides a model of non-alcoholic fatty liver disease in which to study the mech

97 Non-alcoholic fatty liver disease is a serious health proble

98 ion and fibrosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accumula

99 Non-alcoholic fatty liver disease is associated with hepatoc

100 Non-alcoholic fatty liver disease is associated with multipl

101 Steatohepatitis due to non-alcoholic fatty liver disease is developing into a new a

102 The prevalence of non-alcoholic fatty liver disease is increasing worldwide an

103 Non-alcoholic fatty liver disease is the most rapidly growin

104 The progressive non-alcoholic fatty liver disease observed in the LCR rats f

105 (nonalcoholic fatty liver disease) and AFLD (alcoholic fatty liver disease).

106 ty, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cancer.

107 l syndrome, and metabolic (i.e. obesity, non-alcoholic fatty liver disease, and diabetes) and neurolo

108 progression of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatoh

109 r rodents to high-calorie diets promotes non-alcoholic fatty liver disease, characterized by neutral

110 of several metabolic diseases, including non-alcoholic fatty liver disease, diabetes mellitus, and ca

111 h risk factors of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol use, or

112 iet (HFD) consumption is associated with non-alcoholic fatty liver disease, increased apoptosis, and

113 d progression of liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepat

114 also able to reverse already established non-alcoholic fatty liver disease, resulting in significantl

115 Non-alcoholic fatty liver disease, the most prevalent liver

116 tors contributing to the pathogenesis of non-alcoholic fatty liver disease, we examined liver steatos

117 e 2 diabetes mellitus has been linked to non-alcoholic fatty liver disease, which can progress to inf

118 lic diseases such as type 2 diabetes and non-alcoholic fatty liver disease.

119 s responsible for disease progression in non-alcoholic fatty liver disease.

120 latory protein and is highly up-regulated in alcoholic fatty liver disease.

121 atitis C and emergence of cirrhosis from non-alcoholic fatty liver disease.

122 ial for the prevention or treatment of human alcoholic fatty liver disease.

123 ycaemic, hyperinsulinaemic and developed non-alcoholic fatty liver disease.

124 tic link between adipokine dysregulation and alcoholic fatty liver disease.

125 plays a crucial role in the pathogenesis of alcoholic fatty liver disease.

126 reduction contributes to the pathogenesis of alcoholic fatty liver disease.

127 ential therapeutic target for treating human alcoholic fatty liver disease.

128 therapeutic target for diseases such as non-alcoholic fatty liver disease.

129 ential to treat both atherosclerosis and non-alcoholic fatty liver disease.

130 rongly associated with both nonalcoholic and alcoholic fatty liver disease.

131 sent a novel avenue for the treatment of non-alcoholic fatty liver disease.

132 robably increasing the susceptibility to non-alcoholic fatty liver disease.

133 concomitant protection from diet-induced non-alcoholic fatty liver disease.

134 hepatocyte lipoapoptosis are features of non-alcoholic fatty liver disease.

135 modulation of adiponectin-in treating human alcoholic fatty liver disease.

136 tabolic conditions including obesity and non-alcoholic fatty liver disease.

137 atherosclerosis, increased obesity, and non-alcoholic fatty liver disease.

138 might be a novel therapeutic target for non-alcoholic fatty liver disease.

139 MKK2 function confers protection against non-alcoholic fatty liver disease.

140 n implicated in fatty liver formation in non-alcoholic fatty liver disease.

141 egulated de novo lipogenesis involved in non-alcoholic fatty liver disease.

142 vide unique targets for the treatment of non-alcoholic fatty liver disease.

143 therapeutic role of PHLPP2 activators in non-alcoholic fatty liver disease.

144 metabolic outcomes in participants with non-alcoholic fatty liver disease.

145 ction in other hepatic diseases, such as non-alcoholic fatty liver disease.

146 e liver fibrosis, mostly associated with non-alcoholic fatty liver disease.

147 at causes insulin-resistant diabetes and non-alcoholic fatty liver disease.

148 res of the metabolic syndrome, including non-alcoholic fatty liver disease.

149 in-1 can be developed to treat patients with alcoholic fatty liver disease.

150 s (ROS) contribute to the development of non-alcoholic fatty liver disease.

151 promising approach for the treatment of non-alcoholic fatty liver disease.

152 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

153 , atherosclerotic vascular diseases, and non-alcoholic fatty liver disease.

154 adipocyte hypertrophy, and present with non-alcoholic fatty liver disease; 3) DKO mice demonstrate H

155 Patients with non-alcoholic fatty liver had higher (p < 0.001) mean values

156 whether CYP2E1 plays a role in experimental alcoholic fatty liver in an oral ethanol-feeding model.

157 of saturated fat against the development of alcoholic fatty liver in mice is partially mediated thro

158 cate that CYP2E1 contributes to experimental alcoholic fatty liver in this model and suggest that CYP

159 Alcoholic fatty liver is the earliest and most common re

160 r of transcription 3 (STAT3) and ameliorates alcoholic fatty liver, liver injury, and hepatic oxidati

161 mide probe to evaluate their inactivation in alcoholic fatty livers of rats.

162 on of their cysteine or tyrosine residues in alcoholic fatty livers of rats.

163 lipolysis pathway was altered in a model of alcoholic fatty liver, primary hepatocytes from rats fed

164 onsumption contributes to the development of alcoholic fatty liver, which can be overcome by Wy14,643